Published in Hematology Week, September 19th, 2005
In a recent article published in the journal Lung Cancer, scientists in France reported, "This phase II study investigated the efficacy and safety of topotecan in combination with either cisplatin or etoposide in untreated extensive disease SCLC (ED SCLC). Patients with untreated ED SCLC were randomized to treatment with T/C (topotecan 1.25 mg/(m2 day) IV days 1-5, cisplatin 50 mg/m2 IV day 5; 41 patients) or T/E (topotecan .75 mg/(m2 day) IV days 1-5, etoposide 60 mg/(m2day) IV days 1-5; 41 patients)...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hematology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.